Baxter completed the divestiture of its Kidney Care business for $3.71 billion in January 2025, fundamentally restructuring the company while deepening losses despite debt reduction.
The sale of the Kidney Care business (now Vantive Health) represents a major strategic transformation that has meaningfully reduced Baxter's scale and complexity. While the company successfully used proceeds to reduce debt by $3.8 billion, the core business performance has deteriorated significantly, suggesting the remaining operations face substantial operational challenges that require close monitoring.
The divestiture created a smaller, more focused company with total assets declining 22% to $20.1 billion and debt falling 28% to $9.4 billion, reflecting the successful deleveraging from sale proceeds. However, the underlying business performance deteriorated sharply with net losses widening 48% to $957 million despite lower interest expense, while gross profit declined 15% and operating cash flow fell 17%. The financial profile suggests a company that has successfully restructured its balance sheet but is struggling with profitability in its remaining core operations.
Current liabilities reduced — improved short-term financial position and working capital health.
Net income declined 47.5% — review whether driven by operations, interest costs, or non-recurring items.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Debt reduced 28.4% — deleveraging strengthens balance sheet and reduces financial risk.
Liabilities reduced 25.6% — deleveraging improves balance sheet strength and financial flexibility.
Current assets declined 22.4% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 22.2% — asset sales, write-downs, or balance sheet optimization underway.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
R&D spending cut 12.2% — could signal cost discipline or concerning reduction in innovation investment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →